$0.61 0.00 (%) AEterna Zentaris Inc - NASDAQ

Dec. 19, 2014 | 04:00 PM

Partner Headlines

  1. Aeterna Zentaris Adds Hollings Cancer Center To Multi-National Phase 3 Trial In Endometrial Cancer

    Benzinga | Nov. 20, 2014 | 07:32AM EST
  2. Morning Market Losers

    Benzinga | Nov. 6, 2014 | 09:56AM EST
  3. UPDATE: H.C. Wainwright Initiates Coverage On AEterna Zentaris

    Benzinga | Jul. 17, 2014 | 08:51AM EST
  4. Morning Market Losers

    Benzinga | Jan. 9, 2014 | 10:10AM EST
  5. Aeterna Zentaris Announces Proposed Unit Offering; Pricing, Number of Units to be Determined

    Benzinga | Jan. 8, 2014 | 16:14PM EST
  6. Aeterna Zentaris NDA for Macimorelin Acetate in AGHD Accepted for Filing by FDA

    Benzinga | Jan. 6, 2014 | 12:03PM EST
  7. Aeterna Zentaris Names Dr. Richard Sachse as Chief Scientific Officer

    Benzinga | Jan. 3, 2014 | 07:39AM EST
  8. Stocks Hitting 52-Week Lows

    Benzinga | Nov. 20, 2013 | 10:15AM EST
  9. Morning Market Losers

    Benzinga | Nov. 20, 2013 | 09:58AM EST
  10. Aeterna Zentaris Prices 13.1M Unit Offering at $1.15/Unit

    Benzinga | Nov. 20, 2013 | 08:29AM EST
  11. Billionaires Hold Waning Biotechs 42% Off

    GuruFocus | Oct. 13, 2013 | 17:18PM EST
  12. Aeterna Zentaris Closes Transfer of Cetrotide Rights to Merck

    Benzinga | Oct. 1, 2013 | 07:33AM EST
  13. UPDATE: Canaccord Genuity Reiterates Hold Rating, Raises PT on AEterna Zentaris

    Benzinga | Dec. 31, 2012 | 01:35AM EST
  14. Mid-Day Market Movers

    Benzinga | Dec. 28, 2012 | 04:48AM EST
  15. Benzinga's Top Pre-Market Gainers

    Benzinga | Dec. 28, 2012 | 01:14AM EST
  16. Aeterna Zentaris Granted SPA by FDA for Phase 3 AEZS-108 Registration Trial in Endometrial Cancer

    Benzinga | Dec. 28, 2012 | 00:36AM EST
  17. Benzinga's Top Pre-Market Gainers

    Benzinga | Dec. 11, 2012 | 01:17AM EST
  18. Aeterna Zentaris Announces Final Phase 2 Data for Perifosine in Lymphomas to be Presented at Upcoming ASH Meeting

    Benzinga | Nov. 26, 2012 | 00:35AM EST
  19. Aeterna Zentaris Presents Promising Results for Disorazol Z Cytotoxic Conjugates

    Benzinga | Nov. 8, 2012 | 01:25AM EST
  20. Stocks Hitting 52-Week Lows

    Benzinga | Oct. 22, 2012 | 04:12AM EST
  21. Aeterna Zentaris Regains Compliance with NASDAQ $1.00 Minimum Bid Price Rule

    Benzinga | Oct. 22, 2012 | 01:37AM EST
  22. Aeterna Zentaris Announces Pricing of US $16.5 Million Public Offering of Common Shares and Warrants

    Benzinga | Oct. 12, 2012 | 02:57AM EST
  23. Benzinga's Top Pre-Market Losers

    Benzinga | Oct. 12, 2012 | 02:22AM EST
  24. Aeterna Zentaris Announces Proposed Public Offering of Common Shares and Warrants

    Benzinga | Oct. 11, 2012 | 10:14AM EST
  25. Benzinga's Microcap Movers for Thursday September 20, 2012

    Benzinga | Sep. 20, 2012 | 13:56PM EST
  26. Benzinga's Microcap Movers for Monday August 14, 2012

    Benzinga | Aug. 14, 2012 | 11:47AM EST
  27. Aeterna Zentaris Granted Patent in the U.S. for AEZS-130 as Diagnostic Test for Adult Growth Hormone Deficiency

    Benzinga | Aug. 7, 2012 | 01:33AM EST
  28. Six Flags Entertainment, Sanmina-SCI Corporation Among Stocks Gapping Up Tuesday

    FoxBusiness | Jul. 24, 2012 | 04:31AM EST
  29. Aeterna Zentaris Requests Fast Track Designation from the FDA for AEZS-130 as Diagnostic Test for Adult Growth Hormone Deficiency

    Benzinga | Jul. 24, 2012 | 02:41AM EST
  30. Benzinga's Microcap Movers for Tuesday June 26, 2012

    Benzinga | Jun. 26, 2012 | 11:09AM EST
  31. Aeterna Zentaris Announces Final Phase 3 Results for AEZS-130 in Adult Growth Hormone Deficiency Presented at ENDO Meeting

    Benzinga | Jun. 26, 2012 | 01:31AM EST
  32. Aeterna Zentaris: Phase 1 Results Show Perifosine's Activity Against Neuroblastoma

    Benzinga | Jun. 21, 2012 | 01:31AM EST
  33. Aeterna Zentaris Receives Notification from NASDAQ Relating to Minimum Bid Price

    Benzinga | May. 16, 2012 | 10:16AM EST
  34. Keryx Biopharma Trade Lower after Adam Feuerstein's Negative Blog Post

    Benzinga | Mar. 6, 2012 | 00:47AM EST
  35. Aeterna Zentaris Reports Updated Phase 1 Trial Results for AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer; Demonstrated Early Evidence of Antitumor Activity

    Benzinga | Feb. 3, 2012 | 00:39AM EST
  36. Oppenheimer Reduces AEterna Zentaris PT

    Benzinga | Jan. 24, 2012 | 10:31AM EST
  37. Aeterna Zentaris Announces "At-the-Market" Issuance Program of up to $16M

    Benzinga | Jan. 24, 2012 | 00:16AM EST
Trading Center